The peptide agonist-binding site of the glucagon-like peptide-1 (GLP-1) receptor based on site-directed mutagenesis and knowledge-based modelling by Dods, RL & Donnelly, D
Biosci. Rep. (2016) / 36 / art:e00285 / doi 10.1042/BSR20150253
The peptide agonist-binding site of the
glucagon-like peptide-1 (GLP-1) receptor based on
site-directed mutagenesis and knowledge-based
modelling
Rachel L. Dods* and Dan Donnelly*1
*School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, U.K.
Synopsis
Glucagon-like peptide-1 (7–36)amide (GLP-1) plays a central role in regulating blood sugar levels and its receptor,
GLP-1R, is a target for anti-diabetic agents such as the peptide agonist drugs exenatide and liraglutide. In order
to understand the molecular nature of the peptide–receptor interaction, we used site-directed mutagenesis and
pharmacological profiling to highlight nine sites as being important for peptide agonist binding and/or activation.
Using a knowledge-based approach, we constructed a 3D model of agonist-bound GLP-1R, basing the conformation of
the N-terminal region on that of the receptor-bound NMR structure of the related peptide pituitary adenylate cyclase-
activating protein (PACAP21). The relative position of the extracellular to the transmembrane (TM) domain, as well as
the molecular details of the agonist-binding site itself, were found to be different from the model that was published
alongside the crystal structure of the TM domain of the glucagon receptor, but were nevertheless more compatible with
published mutagenesis data. Furthermore, the NMR-determined structure of a high-potency cyclic conformationally-
constrained 11-residue analogue of GLP-1 was also docked into the receptor-binding site. Despite having a different
main chain conformation to that seen in the PACAP21 structure, four conserved residues (equivalent to His-7, Glu-9,
Ser-14 and Asp-15 in GLP-1) could be structurally aligned and made similar interactions with the receptor as their
equivalents in the GLP-1-docked model, suggesting the basis of a pharmacophore for GLP-1R peptide agonists. In
this way, the model not only explains current mutagenesis and molecular pharmacological data but also provides a
basis for further experimental design.
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INTRODUCTION
Glucagon-like peptide-1 (GLP-1) is an ‘incretin’ hormone of 30
residues (Figure 1A) which is released from intestinal L-cells in
response to feeding, whereby it acts at pancreatic β-cells to poten-
tiate insulin secretion in a glucose-dependent manner [1–3]. The
hormone’s central role in post-prandial insulin release, alongside
its other effects such as the inhibition of gastric emptying [4],
the inhibition of glucagon secretion [5] and the reduction in food
intake [6], have resulted in the receptor for GLP-1 (GLP-1R)
becoming a major target for the potential treatment of diabetes.
Indeed, there are two peptides (exenatide and liraglutide) which
are already licensed for use in therapy [7,8].
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GLP-1R is a typical ‘Family B’ G protein-coupled receptor
(GPCR), a family characterized by an extracellular N-terminal
domain (NTD) of 100–150 residues and a TM domain (7TM
domain) consisting of seven TM α-helices (TM1–TM7), the
six connecting loops and a C-terminal tail [9] (Figure 1B).
The proposed model for agonist-induced activation of Family B
GPCRs, including GLP-1R, is a two-step mechanism in which the
C-terminal half of the peptide hormone’s α-helix binds to the
NTD, whereas a second interaction between the N-terminal
residues of the ligand and the 7TM of the receptor leads to re-
ceptor activation [10]. Several X-ray structures of the isolated
NTDs of Family B GPCRs have shown that they share a common
fold stabilized by three conserved disulphide bonds consisting
of an N-terminal α-helix and a short consensus repeat [11–14].
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Figure 1 Sequence and numbering of ligands and receptor residues discussed in this paper
(A) The aligned amino acid sequences of the peptides discussed in the present paper. Note that GLP-1 starts with residue
His-7*, whereas the remaining peptides begin at residue 1. (B) A schematic topological representation (generated using
GPCRDB Tools, http://tools.gpcr.org/) of GLP-1R, annotated to show the regions mutated in the present study (blue:
single mutations, data in main body of paper; red: remaining sites from the initial screen of double mutations, data in
Supplementary Material). Residue numbers of the most interesting sites are highlighted.
More recently, the first crystal structures of the 7TM domain of
two Family B GCPRs, solved in the absence of both the NTD
and the peptide ligand, have recently been described [15,16].
The NTD of GLP-1R binds to the helical region of GLP-1
(residues 24*–33*; residues in the ligand will be distinguished
from those in the receptor throughout the paper by the addition on
an asterisk *) via a shallow groove on the surface of the domain
and the details of this interaction are well understood via X-ray
crystallography [13,14, reviewed in 17]. However, despite the re-
cent publication of the crystal structure of the TM domain of the
closely related glucagon receptor (GlucR; [16]), the details of
the interaction between GLP-1’s N-terminal region and the re-
ceptor remain largely unknown. There are however some data
which inform us of the likely conformation of the N-terminal
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region of the active GLP-1 peptide. Firstly, Inooka et al. [18] pub-
lished the receptor-bound structure of the related peptide pituitary
adenylate cyclase-activating protein (1–21) amide (PACAP21),
solved by proton NMR (2D TRNOE; pdb code 1GEA), which
showed that residues 3*–7* formed a β-coil structure preceded
by an extended N-terminal tail. The N-terminal region of GLP-1
is closely related to that of PACAP (Figure 1A) and may there-
fore fold in a similar manner. Secondly, Hoang et al. [19] have
recently published the NMR structures of several 11-residue ana-
logues of GLP-1 containing cyclic constraints. One such peptide,
containing a disulphide link between homocysteine residues at
positions 2* and 5* (equivalent to residues Ala-8* and Thr-11*
in GLP-1), maintained sub-nanomolar potency in cAMP assays
and was shown by NMR to have a type II β-turn type (pdb code
2N0I), which was also observed in the non-constrained parent
compound.
The aim of this work was to determine a detailed working mo-
lecular model for agonist-docked GLP-1R that accounts for our
current knowledge and that can also act as a basis for the design
of new ligands and further experiments. Following a review of the
published literature relating to the site-directed mutagenesis of
GLP-1R (Supplementary Figure S2; Supplementary Table S1),
we designed an Ala-scan mutagenesis approach targeted at a 17-
residue region of the receptor based around the 3rd extracellular
loop (ECL3) and the neighbouring region of TM7 (Figure 1b).
Mutated receptors were expressed in human embryonic kidney
(HEK)293 cells and analysed using both radioligand-binding ana-
lysis to assess affinity, and cAMP accumulation assays to assess
efficacy. Further sites in ECL2 and TM5 were targeted in a sim-
ilar manner (Figure 1). A molecular model of the full-length
peptide-bound GLP-1R was generated using a knowledge-based
approach by combining three components: the crystal structure
of the NTD bound to GLP-1; a homology model of the 7TM do-
main of GLP-1R based upon the closely related glucagon receptor
crystal structure and a homology model of the N-terminal region
of GLP-1 based upon the receptor-bound structure of the related
peptide PACAP21 solved via NMR [14,16,18]. The mutagenesis
data published here, alongside that from the literature, were used
to inform the docking of the ligand and to suggest the key interac-
tion sites required for agonist binding and activation. To validate
the model, the structure of a cyclic constrained 11-residue GLP-1
analogue ([19]; pdb code 2N0I), which has a different conforma-
tion to that determined for receptor-bound structure of the related
peptide PACAP21 ([18]; pdb code 1GEA), was docked into the
GLP-1R model so that a pharmacophore for peptide agonists
could be determined.
MATERIALS AND METHODS
Constructs
The pcDNA5-FRT vector (Invitrogen) containing the full-length
human GLP-1R [10], was used to express the wild-type receptor.
The mutated cDNA used to express the mutant receptors were
generated using QuikChange site-directed mutagenesis (Strata-
gene), and confirmed by DNA sequencing. These constructs were
used to express the wild-type and mutant GLP-1 receptors in Flp-
In HEK293 cells (Invitrogen).
Cell culture
The Flp-In HEK293 cells were cultured in Dulbecco’s modi-
fied Eagle’s medium (Sigma) supplemented with 10 % foetal calf
serum (Lonza Wokingham Ltd.), 2 mM L-glutamine, 100 unit/ml
penicillin and 100 μg/ml streptomycin (Invitrogen). Cells were
transfected with the pcDNA5.FRT vector and pOG44 using
Lipofectamine® 2000 transfection reagent (Invitrogen) and stable
isogenic clones were selected by the addition of the antibiotic hy-
gromycin (Sigma) at a concentration of 100 μg/ml.
Peptides
GLP-1(7–36)amide (GLP-1) and exendin-4(9–39)amide
[EX4(9–39)] were purchased from Bachem (Saffron Walden).
125I-Bolton-Hunter labelled EX4(9–39) was purchased from
PerkinElmer. The radioligand 125I-GLP-1 was the kind gift of
Novo Nordisk (Copenhagen).
Radioligand binding
Flp-In HEK293 cells, cultured to confluence on five 160-cm2
Petri dishes (pre-coated with poly-D-lysine), were washed with
PBS, followed by the addition of 15 ml of ice-cold sterile double
distilled water to induce cell lysis. Following 5 min incubation
on ice, the ruptured cells were thoroughly washed with ice-
cold PBS before being scraped from the plates and pelleted by
centrifugation in a bench-top centrifuge (13,000 g for 30 min).
The crude membrane pellet was resuspended in 1 ml membrane-
binding solution (MBS; 50 mM HEPES pH 7.4, 2.5 mM CaCl2,
5 mM MgCl2, 0.2 % BSA) and forced through a 23G needle.
Aliquots (0.1 ml) were snap-frozen in liquid nitrogen and stored
at − 70 ◦C. When required for assay, membranes were slowly
thawed on ice before diluting to a concentration that gave total
radioligand binding of <10 % total counts added. In a reac-
tion volume of 200 μl, 75 pM (∼60,000 cpm) of radioligand
[125I-GLP-1 or 125I-exendin(9–39)], various concentrations of
an unlabelled competitor ligand and HEK293 membranes ex-
pressing the receptor of interest were combined, all diluted in
MBS. Assays were carried out for 1 h in MultiScreen 96-well
Filtration Plates (Glass fibre filters, 0.65 μm pore size, Milli-
pore) pre-soaked in 1 % non-fat milk/PBS. After the incubation,
membrane-associated radioligand was harvested by transferring
the assay mixture to the filtration plate housed in a vacuum man-
ifold. The wells of the filtration plate were washed three times
with washing buffer (0.2 ml PBS, 0.1 % BSA) before harvesting
the filter discs. Filter-bound radioactivity was measured in a γ -
counter (RiaStar 5405 counter; PerkinElmer Life and Analytical
Sciences). Total radioligand bound was <10 % and non-specific
binding was ∼1 % of total counts added.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
c© 2016 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution Licence 3.0. 3
R.L. Dods and D. Donnelly
cAMP assays
The LANCE cAMP kit (PerkinElmer Life and Analytical Sci-
ences) was used alongside the manufacturer’s instructions with
some minor adaptations as described. Flp-In HEK293 cells ex-
pressing the receptor of interest were washed and resuspended
in stimulation buffer: HBSS, 5mM HEPES, 0.1 % BSA, 500 μM
IBMX (all from Sigma), pH 7.4, at a concentration of 1 × 106
cells/ml. Cell numbers were set at 2500 cells/well based upon
previous experiments (data not shown), in order that raw fluores-
cence data fell within the linear range determined by a standard
cAMP concentration curve. The Alexa Fluor® 647 labelled anti-
body was added to the cell suspension at a final concentration of
0.005 % (v/v). Ligand concentrations were used in the range of
100 μM to 1 pM made up in the vehicle (stimulation buffer). The
ligand was added as 6 μl/well of each concentration (in triplic-
ate) to a white 384 well low volume OptiPlate (Greiner). To this
was added 6 μl of the prepared cell suspension and the contents
of the plate were mixed, sealed and left for 10 min at 37 ◦C. The
detection mixture was prepared in a separate tube by diluting the
Eu-W8044 labelled streptavidin 2250-fold in the detection buffer
supplied with the kit. The Biotin-cAMP was then added such that
is was diluted 750-fold. This mixture was incubated for at least
30 min at room temperature to allow complex formation to occur.
Once the 10 min agonist stimulation time was complete, 12 μl
of the detection mixture was added to each well and incubated at
room temperature for 1 h. The acceptor fluorescence signal was
then read at 665 nm using Victor TM X4 2030 multi-label plate
reader (PerkinElmer).
Data analysis
Binding and cAMP assays were carried out with triplicate
values at each ligand concentration and with each assay being re-
peated at least three times. The resultant data were analysed using
Prism 6 (GraphPad Software Inc.). IC50 values were calculated
from the competition binding data using non-linear regression
with a three-parameter logistic equation, and then converted to
dissociation constant Ki, using the Cheng and Prusoff equation,
by first calculating the Ki for exendin(9–39) from homologous
competition assays and then using this value to calculate Ki for
GLP-1 from heterologous competition assays [20]. Expression
levels (Bmax) were estimated from the homologous competition
assays using Bmax = B0 × IC50/[L], where [L] is the concentration
of free radioligand and B0 is the specific binding in the absence
of unlabelled ligand. Bmax values were expressed as fmol of re-
ceptor/mg of membrane protein where the latter was calculated
using a bicinchoninic acid protein assay using BSA to create a
standard curve. The cAMP assay data were analysed using both
a logistical and operational model in order to determine potency
(EC50) and efficacy (τ ) (see [21] for equations). When using the
operational model to determine efficacy, the Ki values from
the corresponding binding analyses were used as a constraint
during the non-linear regression. The estimated τ values were
then normalized to cell surface expression using the Bmax val-
ues determined from the binding analysis to give τ c (errors from
both the τ and Bmax estimations were pooled). Efficacies for
mutants were compared with wild-type GLP-1R by comparing
log τ c values using an unpaired two-tailed Student’s t test (un-
equal variance), with P < 0.005 being used as a threshold for a
significant reduction in efficacy.
Molecular modelling
All molecular modelling manipulations (Supplementary Fig-
ure S1) were carried out using the tools embedded within Py-
Mol (The PyMOL Molecular Graphics System, Version 1.7.2.3
Schro¨dinger, LLC) unless otherwise stated. (1) Model 1 from
the ensemble of NMR structures for the receptor-bound structure
of C-terminally truncated PACAP ([18]; pdb code 1GEA) was
(in silico) mutated to the GLP-1 sequence and (2) this was then
structurally aligned with the GLP-1 molecule within the NTD
structure of GLP-1R ([14]; pdb code 3IOL) by superimposing
residues Val-16*–Gly-22*. (3) The structure of the antagonist-
bound structure of the NTD structure of GLP-1R ([13]; pdb code
3C5T) was structurally aligned to the product of stage 2. (4)
The following residues and moieties were then removed from the
product of stage 3: GLP-1 10*–21* from 3IOL; GLP-1 22*–29*
from the mutated 1GEA; all of 3C5T except for residues Ser-129–
Arg-131; all waters and other non-protein atoms. The remaining
atoms were saved to a single pdb file which now represented a
model of the NTD of GLP-1R with GLP-1 bound, as observed
in 3IOL, but with three extra residues fused on to the C-terminus
(Ser-129–Arg-131 from 3C5T) and an N-terminally extended
version of the GLP-1 ligand having the conformation of His-7*–
Glu-21* based upon the receptor-bound PACAP21 structure. (5)
The structure of the 7TM domain of the glucagon receptor ([16];
pdb code 4L6R) was used as a template to model the equivalent
region of GLP-1R using the homology modelling server SWISS-
MODEL ([22]; http://swissmodel.expasy.org/). ECL1 was not
modelled as it was absent from the template structure. (6) The
surface of the product of stage 5 was displayed in PyMol using the
‘Cavities and Pockets Only’ setting, in order to aid the manual
docking of the product of stage 4 as a rigid body by inserting
the N-terminal region of the peptide ligand into the highlighted
cavity of the 7TM domain. During this docking process, the
mutagenesis data from the literature were carefully considered
(Supplementary Figure S2; Supplementary Table S1) and some
local side-chain rotamers were modified and subjected to local
optimization using the ‘Sculpting’ tool in PyMol. Once the dock-
ing had been finalized, the atoms of both components were saved
as a single pdb file and then subjected to optimization using the
KoBaMIN server ([23]; http://csb.stanford.edu/kobamin) to yield
the final model.
RESULTS
ECL3/TM7
A total of 17 single site-directed mutations of residues spanning
Met-371ECL3 to Glu-3877.41 (ECL3/TM7; superscripts refer to
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Figure 2 Pharmacological analysis of two TM7 single mutant re-
ceptors compared with wild-type GLP-1R: Arg-3807.34–Ala, Lys-
3837.37–Ala
(A) Concentration–response curves for GLP-1-induced cAMP accumula-
tion in Flp-In HEK293 cells expressing either hGLP-1R or the mutated re-
ceptors. US, unstimulated. (B) Radioligand competition binding curves,
using 75 pM 125I-EX4(9–39) and unlabelled GLP-1 as competitor, for
membranes derived from Flp-In HEK293 cells expressing either wild–
type GLP-1R or mutated receptors. Replicates are in triplicate with errors
representing S.E.M.
Wootten numbering [21] for TM residues, or else identify the
region in which the residue is located; Figure 1B) were generated
using QuikChange mutagenesis. Stable Flp-In HEK293 cell lines
were selected for each mutant receptor and both LANCE cAMP
assays and radioligand competition assays were carried out in or-
der to estimate their pharmacological properties (Table 1). GLP-1
acting at Arg-3807.34–Ala had a 240-fold reduced potency, with
a 129-fold reduced affinity; whereas at Lys-3837.37–Ala GLP-
1 had 51-fold reduced potency but affinity that was not signi-
ficantly different from wild-type GLP-1R (Figure 2). However,
although the operational model demonstrated that Lys-3837.37–
Ala had significantly reduced efficacy (log τ c = 1.18), this
was not the case for Arg-3807.34–Ala where the reduced potency
could be accounted for by the reduced affinity. GLP-1 acting at
Glu-3877.41–Ala had reduced efficacy (log τ c = 0.52), whereas
Ala-375–GlyECL3 displayed 10-fold reduced affinity. Asp-372–
AlaECL3 and Leu-2847.38–Ala displayed reduced potency but did
not have significantly reduced affinity or efficacy for GLP-1.
ECL2/TM6
An initial double-Ala scan of the region of hGLP-1R span-
ning Ile-2864.62 to Pro-3125.42 (TM4/ECL2/TM5 but excluding
the conserved Cys-296ECL2; Figure 1B) was carried out using
QuikChange mutagenesis. Stable Flp-In HEK293 cell lines were
generated expressing each double mutant receptor and LANCE
cAMP assays were carried out in order estimate the potency of
GLP-1. Membranes derived from these stable cell lines were
used in radioligand competition assays to estimate the percent-
age specific binding of 75 pM 125I-GLP-1, using >10,000-fold
unlabelled GLP-1 as the competitor (Table S2). Six sites were
highlighted by this low resolution pharmacological screen as
being potentially interesting, four of which displayed reduced
specific binding and a reduced potency of more than 250-fold –
hence these sites were analysed in more detail by generating
a further eight single Ala mutants. Flp-In HEK293 cell lines
expressing each of these eight single mutant receptors were ana-
lysed using LANCE cAMP assays and full competition binding
analysis with 125I-EX4(9–39) as the tracer and both GLP-1 and
EX4(9–39) as competitors (Table 1). Although all eight mutant
receptors bound EX4(9–39) with the same affinity, five were
identified as having GLP-1 affinity and/or potency significantly
different from the wild-type receptor (Figure 3): Lys-2884.64–Ala
displayed a 5248-fold reduction in potency but with only a 23-
fold reduction in affinity; Asn-300ECL2–Ala displayed a 95-fold
reduced GLP-1 potency and 36-fold reduction in GLP-1 affinity;
Trp-3065.36–Ala displayed a 191-fold reduced GLP-1 potency
and 110-fold reduction in GLP-1 affinity and Arg-3105.40–Ala
displayed a 1175-fold reduction in potency, despite maintaining
GLP-1 affinity close to that of wild-type GLP-1R. As might be
expected with such large reduction in potency relative to affinity,
the operational model predicted that GLP-1 had reduced efficacy
at Lys-2884.64–Ala and Arg-3105.40–Ala (log τ c = 1.39 and
0.75 respectively). Arg-299ECL2–Ala also displayed significantly
reduced efficacy (log τ c = 0.6). However, log τ c values for
Asn-300ECL2–Ala and Trp-3065.36–Ala were not reduced, sug-
gesting that the reduced potency of GLP-1 at these mutants could
largely be accounted for by reduced GLP-1 affinity (Figure 3).
Molecular modelling
The 7TM domain of the GLP-1R closely resembled that of the
4L6R crystal structure and maintained the interactions between
the residues that form the base of the cavity through two neigh-
bouring polar clusters that link TM1, TM2, TM6 and TM7. Tyr-
1521.47, Arg-1902.60 and Thr-3917.45 form one cluster, whereas
His-3636.52, Glu-3646.53, Glu-3877.41, Thr-3917.45 and Gln-3947.49
form the second. The two networks of interacting side chains
were seen to be linked through Thr-3917.45 and could potentially
also be linked through an interaction between Arg-1902.60 and
Glu-3646.53 via a water molecule, particularly in the ligand-free
model. In the docked model, these clusters of polar residues at the
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Table 1 Pharmacological properties of site-directed mutations of GLP-1R with asterisk (*) representing
data discussed in the text
Numbers in brackets refer to fold-change relative to wild-type (WT) GLP-1R if statistically different from WT GLP-1R.
†P< 0.005, representing a significant reduction in pEC50, pIC50 or log τ c using GLP-1
GLP-1 GLP-1 GLP-1 EX4(9–39) Bmax
Mutant pEC50 log τ c pIC50 pIC50 (pmol/mg)
WT GLP-1R* 11.38 +− 0.15* 1.97 +− 0.14* 9.45 +− 0.09* 8.35 +− 0.31* 21.8 +− 1.5*
K288A4.46* 7.66 +− 0.10 (5248)*† 0.58 +− 0.02*† 8.09 +− 0.08 (23)*† 8.20 +− 0.11 18.1 +− 0.1
Y289A4.65 10.38 +− 0.17 1.89 +− 0.14 9.33 +− 0.04 8.48 +− 0.12 4.3 +− 0.2
R299AECL2* 10.50 +− 0.15 1.37 +− 0.08*† 9.87 +− 0.03 8.59 +− 0.03 8.8 +− 0.2
N300AECL2* 9.40 +− 0.06 (95)*† 2.28 +− 0.06 7.90 +− 0.10 (36)*† 8.53 +− 0.16 3.9 +− 0.3
Y305A5.35 10.70 +− 0.05 (5)*† 2.16 +− 0.06 9.26 +− 0.06 8.29 +− 0.11 4.9 +− 0.3
W306A5.36 * 9.10 +− 0.28 (191)*† 2.09 +− 0.19 7.41 +− 0.05 (110)*† 8.61 +− 0.09 9.0 +− 0.4
I309A5.39 10.20 +− 0.41 1.53 +− 0.29 8.93 +− 0.06 8.31 +− 0.30 16.4 +− 0.8
R310A5.40* 8.31 +− 0.03 (1175)*† 1.22 +− 0.04*† 8.91 +− 0.02 8.37 +− 0.33 4.1 +− 0.7
M371AECL3 10.88 +− 0.14 2.49 +− 0.17 8.65 +− 0.06 8.26 +− 0.12 11.8 +− 0.1
D372AECL3 9.65 +− 0.11 (54)*† 1.84 +− 0.10 8.85 +− 0.15 8.25 +− 0.06 2.9 +− 0.0
E373AECL3 11.16 +− 0.03 2.26 +− 0.02 9.46 +− 0.05 8.39 +− 0.23 6.0 +− 0.0
H374AECL3 11.43 +− 0.11 2.53 +− 0.13 9.57 +− 0.05 8.32 +− 0.18 4.8 +− 0.4
A375GECL3* 10.52 +− 0.16 1.78 +− 0.21 8.46 +− 0.05 (10)*† 7.67 +− 0.32 40.5 +− 1.6
R376AECL3 11.32 +− 0.06 1.94 +− 0.12 9.23 +− 0.02 8.13 +− 0.14 29.9 +− 2.2
G377AECL3 11.01 +− 0.11 2.67 +− 0.16 9.03 +− 0.05 8.32 +− 0.32 4.1 +− 0.4
T378A7.32 11.19 +− 0.02 2.65 +− 0.02 9.50 +− 0.13 8.31 +− 0.26 2.7 +− 0.2
L379A7.33 11.08 +− 0.07 2.49 +− 0.11 9.08 +− 0.03 8.17 +− 0.07 6.8 +− 1.1
R380A7.34* 9.00 +− 0.05 (240)*† 1.79 +− 0.06 7.34 +− 0.01 (129)*† 7.92 +− 0.07 14.8 +− 0.1
F381A7.35 11.18 +− 0.10 2.72 +− 0.11 9.23 +− 0.03 8.31 +− 0.28 3.5 +− 0.3
I382A7.36 11.09 +− 0.03 2.59 +− 0.04 9.10 +− 0.05 8.46 +− 0.33 5.0 +− 0.4
K383A7.37 * 9.67 +− 0.12 (51)*† 0.79 +− 0.18*† 8.92 +− 0.03 8.17 +− 0.25 27.0 +− 2.8
L384A7.38 10.81 +− 0.05 (4)*† 2.23 +− 0.08 8.66 +− 0.01 8.42 +− 0.28 16.9 +− 0.5
F385A7.39 11.42 +− 0.09 2.54 +− 0.11 8.94 +− 0.02 8.32 +− 0.32 18.5 +− 0.9
T386A7.40 11.17 +− 0.14 2.99 +− 0.17 8.91 +− 0.03 8.36 +− 0 06 3.9 +− 0.28
E387A7.41 * 11.03 +− 0.04 1.45 +− 0.05*† 9.91 +− 0.02 8.08 +− 0.25 9.3 +− 0.2
base of the binding cavity interact directly with the N-terminal
region of GLP-1.
The location and environment of the residues of interest high-
lighted by the mutagenesis described above are summarized as
follows (Figure 4). Both Lys-2884.64 and Trp-3065.36 do not dir-
ectly form part of the agonist-binding pocket: Lys-2884.64 is shiel-
ded from the cavity by ECL2, with which it forms several interac-
tions; Trp-3065.36 is on the lipid-facing side of TM5, close to the
extracellular end of the helix. The orientation of Arg-299ECL2 is
ambiguous, with its extended side chain pointing away from the
helical bundle where it could be modelled to interact with either
Glu-2927.49 or Glu-21* and Ser-18*. However, the remaining
residues are in closer proximity to the ligand cavity. Asn-300ECL2
is able to interact with the side chain of Ser-14*, whereas Arg-
3105.40 interacts closely with His-7* and is also in close proximity
to the free main chain carboxy of Ala-3686.57 and the end of TM6.
The neighbouring main chain carboxy of Phe-3676.56 is also free,
and can interact with the side chain of Lys-3837.37, which is in the
vicinity of Ala-8*. Arg-3807.34 at the start of TM7 can interact
directly with Asp-15*, which itself hydrogen bonds to Thr-13*.
Glu-3877.41 interacts with both the main chain carboxy of Ala-8*
and the imidazole ring of His-7* (Figure 4).
Other interaction points observed in the model between the
peptide and the 7TM domain are as follows (Figure 5). In addi-
tion to Arg-299ECL2 and Asn-300 ECL2 on ECL2, Trp-297ECL2 can
interact directly with the ligand and is surrounded by Thr-11*,
Val-16* and Leu-20*. Phe-12* sits in a buried pocket under-
neath ECL2, where it is surrounded by Phe-2303.33, Gln-2343.37,
Thr-298ECL2 and Tyr-3055.35. The 3rd position of the ligand, Glu-
9*, interacts with Trp-1521.47, Arg-1902.60 and Lys-1972.67, with
the closest atom–atom distances (excluding hydrogens) all being
less than 3 ˚A (1 ˚A = 0.1 nm). Other residues that form the re-
gion of the binding cavity in proximity to Glu-9* are Val-1942.64,
Met-2333.36, Leu-3887.42 and Thr-3917.45. The N-terminal H-7*
of GLP-1 is in a region of the cavity made up of Arg-1902.60,
Val-2373.40, Tyr-3055.35, Ile-3095.39, Arg-3105.40, Glu-3646.53,
Phe-3676.56, Ala-3686.58, Glu-3877.41 and Thr-3917.45. Mean-
while, although important for glucagon recognition in the gluca-
gon receptor [16,24], ECL1 does not play a major role in GLP-1
binding to GLP-1R [25] and was not modelled due to its absence
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Figure 3 Pharmacological analysis of four mutant receptors com-
pared with wild-type GLP-1R: Lys-288–Ala4.64, Asn-300–AlaECL2,
Trp-306–Ala5.36 or Arg-310–Ala5.40
(A) Concentration–response curves for GLP-1-induced cAMP accumula-
tion in Flp-In HEK293 cells. US, unstimulated (no GLP-1 added). (B)
Radioligand competition binding curves, using 75 pM 125I-EX4(9–39)
and unlabelled GLP-1 as competitor, for membranes derived from Flp-In
HEK293 cells expressing either wild-type GLP-1R or one of four single
site mutant receptors. Replicates are in triplicate with errors represent-
ing S.E.M.
of a template. However, the missing ECL1 loop can be predicted
to interact with Gly-10*, Thr-11*, Val 16* and Tyr-19*, as these
residues are surface exposed in the vicinity that the missing loop
region is likely to occupy.
Each of the models from the ensemble in the NMR structure
file of pdb code 2N0I, a cyclic constrained synthetic 11-residue
analogue of GLP-1 with high potency, was structurally aligned
with the GLP-1 ligand in the model. Although it did not share
the same backbone conformation as GLP-1, model 11 from the
ensemble was seen to align such that four conserved resides
(the His-7*, Glu-9*, Ser-14* and Asp-15* equivalents in GLP-1)
could be over-laid with the structure of GLP-1 in 3 dimensional
space. Model 11 of 2N0I was manually docked into the binding
site of the GLP-1R model and found to comfortably occupy the
binding cavity without any serious steric issues, while forming
Figure 4 A side view of the GLP-1-docked GLP-1R model from
between TM5 and TM6
GLP-1R is shown in cartoon form in cyan, with the side chains of the
eight residues highlighted by the mutagenesis (Table 1) shown as red
sticks. The ligand is shown with its surface in yellow, with six residues
highlighted by colour and single residue codes.
very similar interactions with His-7*, Glu-9*, Ser-14* and Asp-
15* as seen above with GLP-1 (Figure 6).
DISCUSSION
The critical region of the peptide ligand responsible for GLP-1R
activation has been identified as the extreme N-terminus, trunca-
tion of which results in a significant reduction in GLP-1 potency
[17]. This region of the peptide agonist interacts with the 7TM do-
main of GLP-1R and hence it is expected that the ligand–receptor
interactions critical for agonist-induced receptor activation will
reside in the 7TM region. On the other hand, the N-terminally
truncated antagonist EX4(9–39) interacts predominantly with the
NTD, hence mutations in the core domain would be expected to
have little effect upon its affinity [17]. In the work described
here, we explored the interaction between GLP-1’s N-terminal
region and the 7TM domain of the receptor by using molecular
modelling and Ala-scanning mutagenesis. Despite being the best
option available, an inherent problem in using the 7TM domain of
the glucagon receptor (4L6R) as a template for an agonist-bound
GPCR model is that it probably represents the inactive conform-
ation and hence there must be some conformational movement
envisaged when examining the details of the agonist-binding
site.
The ligand-docked full-length GLP-1R model differed signi-
ficantly from that of Siu et al. [16] (co-ordinates supplied by Dr
Chris de Graaf) both in terms of the relative orientations of the
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
c© 2016 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution Licence 3.0. 7
R.L. Dods and D. Donnelly
NTD with the 7TM domain, and also in the conformation and
placement of the N-terminal region of the agonist within the 7TM
helical bundle (Supplementary Figure S3). The principle differ-
ence in the relative positions of the ligand and 7TM domain are
that the start of the helix (Ser-14*, Asp-15*) in our model inserts
into the 7TM cavity between TM7 (Arg-3807.34) and ECL2 (Asn-
300ECL2), whereas the equivalent region in the model of Siu et al.
inserts between TM7 and the stalk region of TM1. Consequently,
the ligand in our model does not interact directly with the stalk
region but instead is able to interact more closely with residues
in TM5 and TM6, the converse being the case with the model
of Siu et al. Furthermore, the conformation of the N-terminal
region of the peptide in our model closely matches that of the
NMR structure of PACAP21 (pdb code 1GEA), whereas that of
Siu et al. has a more extended conformation. A consequence of
this is that, although the N-terminal His residues in both models
are at a similar depth within the 7TM bundle (albeit that it is shif-
ted sideways and so closer to TM5 and TM6 in our model), other
residues in the Siu et al. model, such as the equivalent residues to
Glu-9* and Phe-12* of GLP-1, are positioned much closer to the
extracellular side of the membrane. Therefore, although the gen-
eric architecture of the models appears similar at first glance, the
molecular details of the binding site are significantly different.
The Ala-scan of ECL3 and the extracellular region of TM7
revealed three residues in TM7 which were involved in agon-
ist recognition – Arg-3807.34, Lys-3837.37 and Glu-3877.41. Arg-
3807.34–Ala displayed significantly reduced affinity (129-fold)
but had wild-type-like efficacy, suggesting that the observed 243-
fold reduction in potency was largely due to the affinity loss. This
side chain is positioned close to Asp-15* (Figure 6B), an import-
ant residue for GLP-1’s affinity and potency [26], which would
account for the properties of the mutant receptor. Moon et al.
[27] have recently published a study in which Arg-3807.34 was
replaced by Asp, resulting in almost a 2000-fold reduction in po-
tency. [Arg9]-GLP-1, which had almost 100-fold lower potency
at wild-type GLP-1R, was shown to have 120-fold improved po-
tency at the Arg-3807.34–Asp mutant, a reciprocal rescue which
strongly implicates the two residues in an interaction. Further-
more, Moon et al. showed that [Arg4]-GLP-1 could also rescue
the Arg-3807.34–Asp mutant, with a decreased potency of 400-
fold at wild type but a 9-fold improved potency at the mutant
receptor. In our model, Gly-10* of GLP-1 interacts with Leu-
3847.38, just one helical turn below Arg-3807.34 and therefore an
Arg at ligand position 4* could easily reach the Asp substitution
at position 3807.34, validating the choice of GLP-1 conforma-
tion based on PACAP21/1GEA (Figure 6A). Lys-3837.37 lies one
helical turn below Arg-3807.34 and lines the binding cavity. Its
substitution by Ala resulted in a significant reduction in GLP-1
efficacy at the mutant receptor, as well as a 50-fold reduction in
affinity. In the model, Lys-3837.37 is in the vicinity of Ala-8* but
too distant (>5 ˚A) to interact directly with the ligand. This leaves
the possibility of there being an intermediate water molecule or,
perhaps the model based on the inactive structure of the glucagon
receptor template masks a closer interaction between Lys-3837.37
and the ligand in the active state. Alternatively, Lys-3837.37 could
H-bond to the free main chain carboxy of Phe-367 at the end of
TM6 which, as discussed below, may form part of a gateway for
the entry of the N-terminal region of the peptide into the 7TM
bundle. The third residue of interest identified in TM7 was Glu-
3877.41, which displayed significantly reduced efficacy compared
with wild-type GLP-1R which correlates with its location in the
model where it interacts directly with the N-terminal His-7* of
GLP-1 and also forms part of the polar network at the base of the
binding cavity.
In previous studies based on the rat GLP-1R, the importance of
both Lys-2884.64 and ECL2 for agonist recognition was demon-
strated [17,28,29]. A detailed study by Koole et al. [30] using
human GLP-1R determined the role of specific residues in pep-
tide binding, highlighting some potential differences with the
observations in the rat receptor (e.g. Lys-2884.64–Ala and Trp-
3065.36–Ala). In order to examine these differences more closely,
we repeated the double Ala scan of ECL2 in human GLP-1R and
followed up the most interesting observations with single residue
substitutions coupled with a more detailed pharmacological char-
acterization. Four residues in the region encompassing ECL2 and
the extracellular ends of TM4 and TM5 were identified as playing
a potential role in GLP-1 binding and/or GLP-1-induced receptor
activation. In contrast with the observation of Koole et al. [30],
Trp-3065.36–Ala was expressed as a functional receptor in our
system, albeit with 190-fold lower GLP-1 potency. However, the
operational model demonstrated that this potency reduction was
not accompanied by a significant reduction in efficacy and could
hence be explained in large part by its 109-fold reduced affin-
ity for GLP-1. The model suggested this residue to be on the
lipid-facing side of TM5 (Figure 4) and close to the phospholipid
head-group region (in a similar manner to Trp-2844.60, which is
also highly sensitive to mutation [33]) where it may play a role in
forming a stabilizing tryptophan–lipid cation–π interaction [31].
Replacement of such Trp residues with Ala may therefore have
an effect on the stability of the receptor, in this case causing an
indirect reduction in affinity in Flp-In HEK293 cells but a com-
plete lack of expression in the different membrane environment
of Flp-In CHO cells. A second tryptophan residue in ECL2, Trp-
297ECL2, was identified as being important for affinity and efficacy
[30] and in this case the model showed that it interacts directly
with both the helical and N-terminal sections of the ligand via
Thr-11*, Val-16* and Leu-20* (Figure 5).
Arg-299ECL2–Ala displayed reduced efficacy which could be
attributed to the removal of a salt bridge interaction with Glu-
292ECL2, a residue which has also been shown to play a role in
GLP-1 efficacy [30]. This putative salt bridge may play an im-
portant structural role, the disruption of which could result in a
disturbance of the agonist-binding site formed by other residues
in ECL2. However, a second possibility is that Arg-299ECL2 in-
teracts with the helical region of the ligand (Figure 4). Runge
et al. [32] showed that the reduced affinity and potency of Ser-
12–glucagon (Lys-12* in native glucagon and the equivalent of
Ser-18* in GLP-1; Figure 1) at the glucagon receptor could be
rescued by the replacement of a region of the sequence (ECL2
and residues in the neighbouring helical regions) with the equi-
valent from GLP-1R. The model suggests that Arg-299ECL2 is the
only divergent residue in this region that can contact the ligand
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Figure 5 A side view of the GLP-1-docked GLP-1R model from
between TM1 and TM2
GLP-1R is shown in cartoon form in cyan, with the side chains of four
residues highlighted by mutagenesis in the literature (Table S1) shown
as green sticks. The ligand is shown with its surface in yellow, with
three residues highlighted by colour and single residue codes.
in the vicinity of Ser-18*, albeit slightly out of range. If this is
the residue responsible for the observation of Runge et al., it sug-
gests a complimentary pairing in GLP-1R between Arg-299 and
Ser-18* which is reversed in the glucagon receptor (Ser-297 to
Lys-12*).
Another residue which appears to be important for the struc-
tural integrity of ECL2 is Lys-2884.64, which is not part of the
binding cavity but instead appears to have the potential to inter-
act with Glu-292ECL2 (Figure 4) and potentially other residues in
ECL2 (Thr-298 ECL2, Ser-301 ECL2 and Asn-304 ECL2). We ob-
served a substantial reduction in GLP-1 potency at Lys-2884.64–
Ala (5289-fold), related to lowered GLP-1 efficacy, which was
accompanied by only a 23-fold decrease in GLP-1 affinity. The
model suggested that Lys-2884.64 may play a critical role in sta-
bilizing ECL2 and hence maintain the correct binding pocket for
the binding of the N-terminal region of peptide agonists. Koole
at al. [30] observed a 125-fold reduction in affinity and undetect-
able cAMP activity for the Lys-2884.64–Ala mutation in GLP-1R.
Although log τ c could therefore not be determined in this case,
their data also appear to support the reduced efficacy observed
at this mutant receptor. However, the Lys-2884.64–Ala mutation
in rat GLP-1R resulted in a much less substantial loss in potency
(250-fold), with a reduction in affinity of 126-fold that was as-
sociated only with peptide agonists but not their N-terminally
truncated analogues [28].
Although the Asn-300ECL2–Ala mutation resulted in 36-fold
reduced affinity and 95-fold reduced potency, the operational
model indicated no significant reduction in efficacy, while Koole
at al. [30] identified this site as being important in both affinity
and efficacy. The model locates Asn-300ECL2 as being in close
proximity to Ser-14* of GLP-1 where it may form a H-bond
(Figure 4). A more substantial reduction in potency was observed
for Arg-3105.40–Ala (over 1000-fold) with a significant reduction
in efficacy but accompanied by no significant decrease in GLP-
1 affinity. These Arg-3105.40–Ala data agree with the study of
Coopman et al. [33], who demonstrated that the Arg-3105.40–Ala
mutation resulted in a 1259-fold reduction in potency with only a
10-fold reduction in affinity. Our model places Arg-3105.40 in the
binding cavity where it can interact directly with the main chain
of His-7* (Figure 4). Truncation of the first two residues of GLP-
1, to yield GLP-1(9–36)amide, resulted in reduced affinity and
a substantial loss of efficacy [17], and hence the residues in the
receptor interacting with the extreme N-terminus of the agonist
would be expected to be critical for receptor activation. Removal
of His-7* and Ala-8* would prevent the peptide interacting with
not only Arg-3105.40, but also Glu-3646.53 and Glu-3877.41 which
form part of the polar network at the base of the binding cavity.
Confidence in the model is further gained since the equivalent
residue to Glu-3877.41 in the related glucagon receptor (Asp-
3857.41) has been functionally linked with Ser-2* of glucagon
(equivalent of Ala-8* in GLP-1) in a study by Runge et al. [32]
in which the mutation Asp-3857.41–Glu was shown to improve
the affinity and potency of Ala-2–glucagon, despite reducing the
affinity and potency of glucagon itself.
In combination with the residues mutated in this and the re-
lated studies discussed above, the GLP-1R model also enables
the rationalization of other data from the literature in order to
explain the agonist-binding site and a basic pharmacophore for
GLP-1R peptide agonists. A key residue in the peptide agon-
ist is Glu-9* which is close to the imidazole ring of His-7* in
the β-coiled PACAP21-based conformation of GLP-1 (Figure 5).
The equivalent residue in the related peptides secretin, VIP and
glucagon have been shown to be in close proximity to the GLP-
1R equivalents Arg-1902.60 and Lys-1972.67 [34–38] and this is in
complete agreement with the model which has Glu-9* interacting
directly with both these basic side chains (Figure 5A). Further-
more, Runge et al. [32] showed that the reduced affinity and po-
tency of Glu-3–glucagon (native glucagon has Gln-3*; Figure 1)
could be rescued by replacing the sequence in the upper half of
the glucagon receptor with GLP-1R, whereas mutagenesis data
for GLP-1R have shown that the mutation of both Arg-1902.60
and Lys-1972.67 to Ala [30,33,39] resulted in reduced affinity of
GLP-1. However, the Arg-1902.60–Ala substitution did not reduce
oxyntomodulin affinity or efficacy, and since oxyntomodulin has
Gln at the 3rd position rather than Glu (Figure 1A), this adds fur-
ther evidence for position 3 of GLP-1 (and its related peptides)
being in close proximity to Arg-1902.60 and Lys-1972.67 (or the
corresponding residues in the related receptors). In addition, the
model suggested that the phenolic hydroxy group of Tyr-1521.47
could also interact with Glu-9*, as well as Arg-1902.60, and muta-
tion of this residue reduced affinity by more than 30-fold [33]. The
substitution of Thr-1491.44, one helical turn above Tyr-1521.47, to
its SNP variant Met, as well as to several other residue types, had
severe effects on affinity and GLP-1 efficacy [40–42]. The model
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Figure 6 Views of the GLP-1R model docked with “model 11” from pdb code 2N0I
(A) View of the GLP-1R model from between TM5 and TM6 for comparison with Figure 4. (B) View of the GLP-1R model from
between TM1 and TM2 for comparison with Figure 5. The ligand is the cyclic constrained synthetic 11-residue analogue
of GLP-1 based on model 11 of pdb code 2N0I, and is shown as space-fill in yellow, but with four conserved residues
highlighted by colour and single residue codes.
shows that Thr-1491.44 interacts with Asp-1982.68 which forms
a polar interaction that has also been shown to be important in
GLP-1 affinity and potency [43], suggesting the importance of
the interaction between TM1 and TM2 in maintaining the struc-
tural integrity of the binding site close to the interaction site with
Glu-9*. Overall, the model suggests that the N-terminus of GLP-
1 binds to several polar residues close to the base of the binding
pocket where it is likely to disrupt the polar networks and so
trigger conformational change and receptor activation.
An interesting and necessary issue to consider in defining the
peptide-binding site of GLP-1R is that of GLP-1(1–36)amide, the
physiological N-terminally extended precursor to GLP-1, which
is a full agonist at GLP-1R with 50-fold lower potency [30]. Given
that His-7* of GLP-1 is buried within the 7TM bundle, how
can the additional six N-terminal residues be accommodated?
Analysis of the GLP-1-bound GLP-1R model shows that part of
the agonist-occupied binding cavity remains empty and that this
‘residual pocket’ is accessible via an opening situated between
the top of TM5 (Asn-300ECL2, Asn-302ECL2, Trp-3065.36) and
the TM6/ECL3 interface (Phe-2694.45, Asp-3724.48). The residual
pocket is lined by Asn-300ECL2, Asn-302ECL2, Tyr-3055.35, Trp-
3065.36, Arg-3105.40, Phe-3676.56, Ala-3686.57, Phe-3696.58, Met
371ECL2, Asp-372ECL2, Arg-3807.34 and Lys-3837.37, with the base
being formed by two free main chain carboxy groups at the C-
terminal end of TM6. Koole et al. [30] have shown that the
mutation of several of residues in ECL2 resulted in selective
effects on GLP-1(1–36)amide – in particular, Tyr-3055.35–Ala
has no significant effect on GLP-1 efficacy but resulted in a
substantial reduction in the efficacy of GLP-1(1–36)amide (log
τ c = 1.08). We propose that the N-terminal extension of GLP-
1(1–36)amide is accommodated in the binding site through the
doubling back of the N-terminal region of the peptide chain,
which changes direction at His-7* at the base of the cavity, and
then travels back up through the residual pocket and out through
the opening where the N-terminal residues would be expected to
reach the extracellular environment (Supplementary Figure S4).
Yang et al. [44] have recently highlighted the mobility of the
NTD relative to the 7TM domain, mediated through the stalk
region, and the stabilization of an open conformation by agonist
binding. The implication is that the inactive conformation is a
closed state and such a model would help to explain the proper-
ties of a non-peptidic antagonist T-0632 [45], the binding site of
which has been linked with Trp-33NTD on the external solvent-
accessible face of the helix of the NTD, where it is difficult to
envisage its antagonistic mechanism. However, the consideration
of a closed state in which the NTD interacts with the 7TM domain
provides the possibility of an antagonist-binding site composed
of residues on both domains and a mechanism of antagonism
based upon stabilizing the closed state and thereby impeding
agonist action, rather than directly blocking the agonist-binding
site (Supplementary Figure S5). Furthermore, the mobility of
the ligand-bound NTD may enable the N-terminal region of the
peptide to come into transient contact with sites on the 7TM do-
main outside the binding site, which may explain some of the
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benzoylphenaline cross-linking data that predicts some peptide–
receptor interactions that, taken together, provide distance re-
straints which are difficult to reconcile both with each other and
with the current model of the GLP-1R-binding site [46–48] (Sup-
plementary Figure S5).
Following the first stage in the two domain model for Family
B GPCR agonist recognition, the ligand is bound to the NTD. To
complete the second stage, the N-terminus needs to gain access
to the cavity, and, given the constraints posed by it being bound
to the NTD, one way this could be achieved is via a ‘pendulum-
like’ motion in which the NTD–ligand complex rotates via a pivot
point in the stalk, and moves the N-terminal region of the ligand
through an opening between TM5 and TM6/ECL3 and into the
main cavity (Supplementary Figure S5). An opening between
TM5 and TM6 can be seen both in the glucagon receptor crystal
structure and also in the CRF1 receptor, the other known structure
of the 7TM domain of a Family B GPCR, suggesting that this
feature may be common across the class (Supplementary Figures
S6A and S6B). The transition of the N-terminal region of the pep-
tide through this gap would explain the disulfide-trapping data
obtained from the related PTH1 receptor in which four residues
at the TM5/TM6 interface were each individually mutated to
Cys and then disulfide cross-linked to an analogue of parathyroid
hormone (PTH) with Cys at position 1 [49]. The equivalent posi-
tions in the 4L6R crystal structure reveal that one of these residues
(Leu-3685.44–Cys) is on the lipid-facing site of TM5 and hence
inaccessible to the N-terminal region of the ligand from the main
cavity in the 7TM domain (Supplementary Figure S7). However,
passage of the N-terminal region through the opening between
TM5 and TM6/ECL3 would explain how the Cys at position 1
of the ligand was able to come into contact with the lipid-facing
cysteine side chain at residue position 5.44.
In conclusion, we have constructed a molecular model of GLP-
1R which combines the known information from several crystal-
lographic and NMR studies, and we have used a wealth of phar-
macological data generated from site-directed mutagenesis of
GLP-1R to inform and explain the docking of the N-terminus
of GLP-1 into the cavity of the 7TM domain of the receptor.
Further examination of the model enabled an informed predic-
tion of how residues 1*–6* of the N-terminally extended ligand
GLP-1(1–36) could be accommodated in the binding site, as well
as identifying the likely mechanism for entry of the N-terminal
region of the ligand into the 7TM domain cavity. Identification of
key interaction points between the ligand and receptor were used
to predict a basic pharmacophore and to dock an 11-residue ana-
logue of GLP-1 into the receptor-binding site, despite it having
a different main chain conformation to GLP-1 itself. The model
(model co-ordinates available from corresponding author upon
request) provides a valuable tool for the prediction and rational-
ization of further experiments.
AUTHOR CONTRIBUTION
Rachel Dods carried out the mutagenesis, binding and cAMP as-
says and contributed to the data analysis. Dan Donnelly carried
out the molecular modelling, contributed to the data analysis and
wrote the paper.
ACKNOWLEDGEMENTS
We thank Novo Nordisk for the gift of 125I-GLP-1.
REFERENCES
1 Baggio, L.L. and Drucker, D.J. (2007) Biology of incretins: GLP-1
and GIP. Gastroenterology 132, 2131–2157
CrossRef PubMed
2 Drucker, D.J. (2001) Minireview: the glucagon-like peptides.
Endocrinology 142, 521–527 CrossRef PubMed
3 Kieffer, T.J. and Habener, J.L. (1999) The glucagon-like peptides.
Endocr. Rev. 20, 876–913 CrossRef PubMed
4 Wettergren, A., Schjoldager, B., Mortensen, P.E., Myhre, J.,
Christiansen, J. and Holst, J.J. (1993) Truncated GLP-1
(proglucagon 78–107-amide) inhibits gastric and pancreatic
functions in man. Dig. Dis. Sci. 38, 665–673
CrossRef PubMed
5 Ørskov, C. and Nielsen, J.H. (1988) Truncated glucagon-like
peptide-1 (proglucagon 78–107 amide), an intestinal
insulin-releasing peptide, has specific receptors on rat insulinoma
cells (RIN 5AH). FEBS Lett. 229, 175–178
CrossRef PubMed
6 Turton, M.D., O’Shea, D., Gunn, I., Beak, S.A., Edwards, C.M.B.,
Meeran, K., Choi, S.J., Taylor, G.M., Heath, M.M., Lambert, P.D.
et al. (1996) A role for glucagon-like peptide-1 in the central
regulation of feeding. Nature 379, 69–72
CrossRef PubMed
7 Knudsen, L.B., Agerso, H., Bjenning, C. and Holst, J.J. (2001)
GLP-1 derivatives as novel compounds for the treatment of type 2
diabetes: selection of NN2211 for clinical development. Drugs
Future 26, 677–685 CrossRef
8 DeFronzo, R.A., Ratner, R.E., Han, J., Kim, D.D., Fineman, M.S.
and Baron, A.D. (2005) Effects of exenatide (exendin-4) on
glycemic control and weight over 30 weeks in metformin-treated
patients with type 2 diabetes. Diabetes Care 28, 1092–1110
CrossRef PubMed
9 Mayo, K.E., Miller, L.J., Bataille, D., Dalle, S., Goke, B., Thorens, B.
and Drucker, D.J. (2003) International union of pharmacology.
XXXV. The glucagon receptor family. Pharmacol. Rev. 55, 167–194
CrossRef PubMed
10 Mann, R.J., Nasr, N.E., Sinfield, J.K., Paci, E. and Donnelly, D.
(2010) The major determinant of exendin-4/glucagon-like peptide
1 differential affinity at the rat glucagon-like peptide 1 receptor
N-terminal domain is a hydrogen bond from Ser-32 of exendin-4.
Br. J. Pharmacol. 160, 1973–1984 CrossRef PubMed
11 Parthier, C., Kleinschmidt, M., Neumann, P., Rudolph, R., Manhart,
S., Schlenzig, D., Fangha¨nel, J., Rahfeld, J.U., Demuth, H.U. and
Stubbs, M.T. (2007) Crystal structure of the incretin-bound
extracellular domain of a G protein-coupled receptor, Proc. Natl.
Acad. Sci. U.S.A. 104, 13942–13947 CrossRef
12 Pioszak, A.A., Parker, N.R., Suino-Powell, K. and Xu, H.E. (2008)
Molecular recognition of corticotropin-releasing factor by its
G-protein-coupled receptor CRFR1, J. Biol. Chem. 283,
32900–32912 CrossRef
13 Runge, S., Thøgersen, H., Madsen, K., Lau, J. and Rudolph, R.
(2008) Crystal structure of the ligand-bound glucagon-like
peptide-1 receptor extracellular domain. J. Biol. Chem. 283,
11340–11347 CrossRef PubMed
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
c© 2016 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution Licence 3.0. 11
R.L. Dods and D. Donnelly
14 Underwood, C.R., Garibay, P., Knudsen, L.B., Hastrup, S., Peters,
G.H., Rudolph, R. and Reedtz-Runge, S. (2010) Crystal structure of
glucagon-like peptide-1 in complex with the extracellular domain of
the glucagon-like peptide-1 receptor. J. Biol. Chem. 285, 723–730
CrossRef PubMed
15 Hollenstein, K., Kean, J., Bortolato, A., Cheng, R.K.Y., Dore´, A.S.,
Jazyeri, A., Cooke, R.M., Weir, M. and Marshall, F.H. (2013)
Structure of class B GPCR corticotropin-releasing factor receptor 1.
Nature 449, 438–443 CrossRef
16 Siu, F.Y., He, M., de Graffe, C., Han, G.W., Yang, D., Zhang, Z.,
Zhou, C., Xu, Q., Wacker, D., Joseph, J.S. et al. (2013) Structure of
the human glucagon class B G-protein-coupled receptor 1. Nature
449, 444–449 CrossRef
17 Donnelly, D. (2012) The structure and function of the glucagon-like
peptide-1 receptor and its ligands. Br. J. Pharmacol. 166, 27–41
CrossRef PubMed
18 Inooka, H., Ohtaki, T., Kitahara, O., Ikegami, T., Endo, S., Kitada,
C., Ogi, K., Onda, H., Fujino, M. and Shirakawa, M. (2001)
Conformation of a peptide ligand bound to its G-protein coupled
receptor. Nat. Struct. Biol. 8, 161–165
CrossRef PubMed
19 Hoang, H.N., Song, K., Hill, T.A., Derksen, D.R., Edmonds, D.J.,
Kok, W.M., Limberakis, C., Liras, S., Loria, P.M., Mascitti, V. et al.
(2015) Short hydrophobic peptides with cyclic constraints are
potent glucagon-like peptide-1 receptor (GLP-1R) agonists. J. Med.
Chem. 58, 4080–4085
CrossRef PubMed
20 Cheng, Y. and Prusoff, W.H. (1973) Relationship between the
inhibition constant (Ki) and the concentration of inhibitor which
causes 50 per cent inhibition (I50) of an enzymatic reaction.
Biochem. Pharmacol. 22, 3099–3108
CrossRef PubMed
21 Wootten, D., Simms, J., Miller, L.J., Christopoulos, A. and Sexton,
P.M. (2013) Polar transmembrane interactions drive formation of
ligand-specific and signal pathway-biased family B G
protein-coupled receptor conformations. Proc. Natl. Acad. Sci.
U.S.A. 110, 5211–5216 CrossRef PubMed
22 Biasini, M., Bienert, S., Waterhouse, A., Arnold, K., Studer, G.,
Schmidt, T., Kiefer, F., Cassarino, T.G., Bertoni, M., Bordoli, L. and
Schwede, T. (2014) SWISS-MODEL: modelling protein tertiary and
quaternary structure using evolutionary information. Nucleic Acids
Res. 42, W252–W258 CrossRef PubMed
23 Rodrigues, J.P., Levitt, M. and Chopra, G. (2012) KoBaMIN: a
knowledge-based minimization web server for protein structure
refinement. Nucleic Acids Res. 40, W323–W328
CrossRef PubMed
24 Roberts, D.J., Vertongen, P. and Waelbroeck, M. (2011) Analysis of
the glucagon receptor first extracellular loop by the substituted
cysteine accessibility method. Peptides 32, 1593–1599
CrossRef PubMed
25 Lo´pez de Maturana, R., Treece-Birch, J., Abidi, F., Findlay, J.B. and
Donnelly, D. (2004) Met-204 and Tyr-205 are together important
for binding GLP-1 receptor agonists but not their N-terminally
truncated analogues. Protein Pept. Lett. 11, 15–22
CrossRef PubMed
26 Adelhorst, K., Hedegaard, B.B., Knudsen, L.B. and Kirk, O. (1994)
Structure–activity studies of glucagon-like peptide-1. J. Biol. Chem.
269, 6275–6278 PubMed
27 Moon, M.J., Lee, Y.N., Park, S., Reyes-Alcaraz, A., Hwang, J.I.,
Millar, R.P., Choe, H. and Seong, J.Y. (2015) Ligand binding pocket
formed by evolutionarily conserved residues in the glucagon-like
peptide-1 (GLP-1) receptor core domain. J. Biol. Chem. 290,
5696–5706 CrossRef PubMed
28 Al-Sabah, S. and Donnelly, D. (2003) The positive charge at
Lys-288 of the glucagon-like peptide-1 (GLP-1) receptor is
important for binding the N-terminus of peptide agonists. FEBS
Lett. 553, 342–346 CrossRef PubMed
29 Mann, R.J., Al-Sabah, S., de Maturana, R.L., Sinfield, J.K. and
Donnelly, D. (2010) Functional coupling of Cys-226 and Cys-296 in
the glucagon-like peptide-1 (GLP-1) receptor indicates a disulfide
bond that is close to the activation pocket. Peptides 31,
2289–2293 CrossRef PubMed
30 Koole, C., Wootten, D., Simms, J., Miller, L.J., Christopoulos, A.
and Sexton, P.M. (2012) Second extracellular loop of human
glucagon-like peptide-1 receptor (GLP-1R) has a critical role in
GLP-1 peptide binding and receptor activation. J. Biol. Chem. 287,
3642–3658 CrossRef PubMed
31 Sanchez, K.M., Kang, G., Wu, B. and Kim, J.E. (2011)
Tryptophan–lipid interactions in membrane protein folding probed
by ultraviolet resonance Raman and fluorescence spectroscopy.
Biophys. J. 100, 2121–2130
CrossRef PubMed
32 Runge, S., Gram, C., Bra¨uner-Osborne, H., Madsen, K., Knudsen,
L.B. and Wulff, B.S. (2003) Three distinct epitopes on the
extracellular face of the glucagon receptor determine specificity for
the glucagon amino terminus. J. Biol. Chem. 278, 28005–28010
CrossRef PubMed
33 Coopman, K., Wallis, R., Robb, G., Brown, A.J., Wilkinson, G.F.,
Timms, D. and Willars, G.B. (2011) Residues within the
transmembrane domain of the glucagon-like peptide-1 receptor
involved in ligand binding and receptor activation: modelling the
ligand-bound receptor. Mol. Endocrinol. 25, 1804–1818
CrossRef PubMed
34 Vilardaga, J.P., di Paolo, E., de Neef, P., Waelbroeck, M., Bollen, A.
and Robberecht, P. (1996) Lysine 173 residue within the first
exoloop of rat secretin receptor is involved in carboxylate moiety
recognition of Asp 3 in secretin. Biochem. Biophys. Res. Commun.
218, 842–846
CrossRef PubMed
35 Di Paolo, E., Vilardaga, J.P., Petry, H., Moguilevsky, N., Bollen, A.,
Robberecht, P. and Waelbroeck, M. (1999) Role of charged amino
acids conserved in the vasoactive intestinal polypeptide/secretin
family of receptors on the secretin receptor functionality. Peptides
20, 1187–1193
CrossRef PubMed
36 Solano, R.M., Langer, I., Perret, J., Vertongen, P., Juarranz, M.G.,
Robberecht, P. and Waelbroeck, M. (2001) Two basic residues of
the h-VPAC1 receptor second transmembrane helix are essential
for ligand binding and signal transduction. J. Biol. Chem. 276,
1084–1088 CrossRef PubMed
37 Vertongen, P., Solano, R.M., Perret, J., Langer, I., Robberecht, P.
and Waelbroeck, M. (2001) Mutational analysis of the human
vasoactive intestinal peptide receptor subtype VPAC(2): role of
basic residues in the second transmembrane helix. Br. J.
Pharmacol. 133, 1249–1254
CrossRef PubMed
38 Perret, J., Van Craenenbroeck, M., Langer, I., Vertongen, P.,
Gregoire, F., Robberecht, P. and Waelbroeck, M. (2002) Mutational
analysis of the glucagon receptor: similarities with the vasoactive
intestinal peptide (VIP)/pituitary adenylate cyclase-activating
peptide (PACAP)/secretin receptors for recognition of the
ligand’s third residue. Biochem. J. 362, 389–394
PubMed
39 Xiao, Q., Jeng, W. and Wheeler, M.B. (2000) Characterization of
glucagon-like peptide-1 receptor-binding determinants. J. Mol.
Endocrinol. 25, 321–335 CrossRef PubMed
40 Beinborn, M., Worrall, C.I., McBride, E.W. and Kopin, A.S. (2005) A
human glucagon-like peptide-1 receptor polymorphism results in
reduced agonist responsiveness. Regul. Pept. 130, 1–6
CrossRef PubMed
41 Koole, C., Wootten, D., Simms, J., Valant, C., Miller, L.J.,
Christopoulos, A. and Sexton, P.M. (2011) Polymorphism and
ligand dependent changes in human glucagon-like peptide-1
receptor (GLP-1R) function: allosteric rescue of loss of function
mutation. Mol. Pharm. 80, 486–497 CrossRef
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12 c© 2016 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution Licence 3.0.
Peptide agonist-binding site of GLP-1R
42 Koole, C., Wootten, D., Simms, J., Miller, L.J., Christopoulos, A.
and Sexton, P.M. (2015) Differential impact of amino acid
substitutions on critical residues of the human glucagon-like
peptide-1 receptor involved in peptide activity and small-molecule
allostery. J. Pharm. Exp. Ther. 353, 52–63
CrossRef
43 Lo´pez de Maturana, R. and Donnelly, D. (2002) The glucagon-like
peptide-1 receptor binding site for the N-terminus of GLP-1
requires polarity at Asp198 rather than negative charge. FEBS
Lett. 530, 244–248 CrossRef PubMed
44 Yang, L., Yang, D., de Graaf, C., Moeller, A., West, G.M.,
Dharmarajan, V., Wang, C., Siu, F.Y., Song, G., Reedtz-Runge, S.
et al. (2015) Conformational states of the full-length glucagon
receptor. Nat. Commun. 6, 7859 CrossRef PubMed
45 Tibaduiza, E.C., Chen, C. and Beinborn, M. (2001) A small
molecule ligand of the glucagon-like peptide 1 receptor targets its
amino-terminal hormone binding domain. J. Biol. Chem. 276,
37787–37793 PubMed
46 Miller, L.J., Chen, Q., Lam, P.C., Pinon, D.I., Sexton, P.M., Abagyan,
R. and Dong, M. (2011) Refinement of glucagon-like peptide 1
docking to its intact receptor using mid-region photolabile probes
and molecular modeling. J. Biol. Chem. 286, 15895–15907
CrossRef PubMed
47 Chen, Q., Pinon, D.I., Miller, L.J. and Dong, M. (2010) Spatial
approximations between residues 6 and 12 in the amino-terminal
region of glucagon-like peptide 1 and its receptor: a region critical
for biological activity. J. Biol. Chem. 285, 24508–24518
CrossRef PubMed
48 Chen, Q., Pinon, D.I., Miller, L.J. and Dong, M. (2009) Molecular
basis of glucagon-like peptide 1 docking to its intact receptor
studied with carboxyl-terminal photolabile probes. J. Biol. Chem.
284, 34135–34144 CrossRef PubMed
49 Monaghan, P., Thomas, B.E., Woznica, I., Wittelsberger, A., Mierke,
D.F. and Rosenblatt, M. (2008) Mapping peptide
hormone–receptor interactions using a disulfide-trapping approach.
Biochemistry 47, 5889–5895 CrossRef PubMed
Received 30 August 2015/6 November 2015; accepted 9 November 2015
Accepted Manuscript online 23 November 2015, doi 10.1042/BSR20150253
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
c© 2016 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution Licence 3.0. 13
